Phaseline

Companies › Blueprint Medicines

Blueprint Medicines: clinical trials, targets and expected readouts

4 active drug programs in 10 registered trials: 6 Phase 2, 3 Phase 1, 1 Phase 4; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Avapritinib (BLU-285)
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 4Mastocytosis, Systemic; Indolent Systemic Mastocytosis; AML (Acute Myelogenous Leukemia); Anatomic Stage IV Breast Cancer AJCC v8 …Jun 2027
BLU-808
Wild type KIT inhibitor
KITPhase 2Chronic Inducible UrticariaDec 2026
Elenestinib (BLU-263)
KIT inhibitor
KITPhase 2Indolent Systemic MastocytosisSep 2032
BLU-924 (SAR449336)
pan-KRAS inhibitor
KRASPhase 1Advanced Solid TumorSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06783790Avapritinib (BLU-285)Phase 2AML (Acute Myelogenous Leukemia)OncologyDec 2026
NCT04771520Avapritinib (BLU-285)Phase 2Anatomic Stage IV Breast Cancer AJCC v8OncologyDec 2026
NCT06931405BLU-808Phase 2Chronic Inducible UrticariaImmunologyDec 2026
NCT06316960Avapritinib (BLU-285)Phase 2AML, ChildhoodOncologyMar 2027
NCT06327685Avapritinib (BLU-285)Phase 1Systemic Mastocytosis With an Associated Hematologic NeoplasmOncologyMar 2027
NCT07028073Avapritinib (BLU-285)Phase 1Acute Myeloid Leukemia With T(8;21)(Q22;Q22)OncologyMay 2027
NCT03731260Avapritinib (BLU-285)Phase 2Indolent Systemic MastocytosisOncologyJun 2027
NCT06748001Avapritinib (BLU-285)Phase 4Mastocytosis, SystemicOncologyDec 2027
NCT07629960BLU-924 (SAR449336)Phase 1Advanced Solid TumorOncologySep 2029
NCT04910685Elenestinib (BLU-263)Phase 2Indolent Systemic MastocytosisOncologySep 2032

Targets

KIT (3) PDGFRA (1) KRAS (1)

Companies with the same targets

Revolution Medicines Novartis Deciphera Pharmaceuticals Daiichi Sankyo Jiangsu HengRui Medicine Roche Chia Tai Tianqing Pharmaceutical Group TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Eli Lilly

Companies built like this

Genfleet Therapeutics (Shanghai) Deciphera Pharmaceuticals Cogent Biosciences HUYABIO International Ranok Therapeutics (Hangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.